Program
dezandrodeg
Also written as “BMS-986365” and “CC-94676”.
Its studies are mostly in Prostatic Neoplasms, led by Bristol-Myers Squibb.
Furthest: phase 3, since Dec 17, 20245 company-led studies, 1 open or runningNext primary completion: Sep 12, 2027 (phase 3)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Bristol-Myers Squibb | 51 open or running | phase 3since Dec 17, 2024 | May 29, 2020 | Sep 12, 2027phase 3 · NCT06764485 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- May 29, 2020First study: phase 1 study in Prostatic NeoplasmsFirst studyNCT04428788 · 131 enrolled · United States
- May 13, 20242 phase 1 studiesNCT06417229, NCT06433505
- Dec 17, 2024Phase 3 study in Prostatic NeoplasmsNCT06764485 · 960 enrolled · United States, Argentina, Australia and more
- Nov 17, 2025Phase 1 study in Healthy VolunteersNCT07242781 · 22 enrolled · United States
Ahead
- Sep 12, 2027Primary completion: phase 3 study in Prostatic NeoplasmsNCT06764485
TargetBeta
AR →read by rule
“An orally bioavailable androgen receptor (AR) degrader, ”NCIt, by rule
Other programs on AR
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| enzalutamiderule | Astellas Pharma | phase 4 | 69 |
| apalutamiderule | Johnson & Johnson | phase 4 | 31 |
| darolutamiderule | Bayer | phase 4 | 26 |
| Clascoteronerule | cassiopea-spa | phase 4 | 19 |
| ostarinerule | gtx | phase 3 | 15 |
| rezvilutamiderule | Jiangsu HengRui Medicine | phase 3 | 13 |
| Cyproterone Acetaterule | Eurofarma Laboratorios | phase 3 | 4 |
| Androgen Receptor-targeting Regulated Induced Proximity Targeting Chimera HLD-0915 | Johnson & Johnson | phase 3 | 3 |
| HRS-5041 | Jiangsu HengRui Medicine | phase 2 | 6 |
| luxdegalutamide | Novartis | phase 2 | 3 |
| luxdegalutamide | Novartis | phase 2 | 2 |
| Androgen Receptor Degrader AZD9750rule | AstraZeneca | phase 2 | 1 |
Studies
All 5 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07242781Healthy Volunteers · United States | 1 | Terminated | Apr 9, 2026 | 22 |
| NCT06764485Prostatic Neoplasms · United States, Argentina, Australia and more | 3 | Active, not recruiting | Sep 12, 2027 | 960 |
| NCT06433505Healthy Volunteers · United States | 1 | Completed | Feb 14, 2025 | 24 |
| NCT06417229Healthy Participants · United States | 1 | Completed | Feb 19, 2025 | 102 |
| NCT04428788Prostatic Neoplasms · United States | 1 | Completed | Oct 28, 2025 | 131 |
How it is read
Names in the registry
- “BMS-986365”, 4 entries
- “CC-94676”, 1 entry
Conditions, from the studies’ own filings
- Prostatic Neoplasms, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.